Stanford University, USA
Cilia is an open access peer-reviewed journal that publishes high quality basic and translational research on the biology of cilia and diseases associated with ciliary dysfunction. Research approaches include cell and developmental biology, use of model organisms, and human and molecular genetics.
Peter Jackson is a Professor in the Baxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, at the Stanford University School of Medicine. Dr. Jackson returned to Stanford in 2013 after eight years as a Staff Scientist and Director at Genentech Inc. in S. San Francisco, California. At Genentech, he helped define and implement the development of therapeutics for cancer pathways including cell cycle checkpoints, stress pathways, and tumor metabolism. Before joining Genentech in 2005, he spent 10 years on the faculty at Stanford University School of Medicine. His laboratory has been involved in studies of cell cycle biochemistry, regulation of the cancer by kinases and phosphatases, the ubiquitin-proteasome system, and the discovery of a new physiological class of competitive (“pseudosubstrate”) E3 ubiquitin ligase inhibitors, exemplified by the APC/C regulator Emi1.
Since 2005, his lab has focused on signaling through the primary cilium, using proteomic approaches to define regulatory networks and new disease genes. More broadly, the lab has connected many proteins defective in human diseases and cancer to new complexes and pathways, with a view to discovering molecular signatures for diagnostics and therapeutic development. His research has earned him numerous visiting lectureships and honors, including awards from the Baxter Foundation, Howard Hughes Medical Institute, the American Cancer Society, the Pluto Society, and being a Stanford Hume Faculty Scholar and a Kirsch Scholar, and elected a Fellow of the American Association for the Advancement of Science (in 2008).